Clenil Modulite

How to order Clenil Modulite

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Clenil Modulite on Prescriptsy

Clenil Modulite is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Clenil Modulite is a pressurised metered-dose inhaler (pMDI) containing beclometasone dipropionate, an inhaled corticosteroid (ICS) licensed in the United Kingdom for the regular preventive management of asthma.

It uses a CFC-free propellant (HFA-134a), which is ozone-friendly and produces a consistent fine aerosol for reliable drug delivery to the airways.

Clenil Modulite is available in strengths of 50, 100, 200, and 250 micrograms per actuation, allowing dose adjustment to suit patients with mild, moderate, or severe persistent asthma.

Asthma affects approximately 5.4 million people in the UK and remains a leading cause of emergency hospital admissions, particularly during autumn and winter.

Regular use of a preventer inhaler such as Clenil Modulite is the cornerstone of long-term asthma management, reducing airway inflammation, preventing symptoms, and lowering the risk of severe exacerbations.

This page provides a comprehensive clinical overview of how Clenil Modulite works, correct inhaler technique, dosing guidance, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Clenil Modulite

Before reading further, note the following key safety points about Clenil Modulite.

• Clenil Modulite is a preventer inhaler. It must not be used to relieve sudden breathlessness, wheeze, or chest tightness. Always carry a separate reliever inhaler (such as salbutamol) for acute symptoms.
• Do not stop Clenil Modulite suddenly. If your prescriber advises stopping or reducing the dose, this should be done gradually to avoid the risk of adrenal insufficiency.
• Rinse your mouth with water and spit after every inhalation to reduce the risk of oral thrush and hoarseness.
• If your asthma is worsening despite regular preventer use, seek medical review rather than increasing the dose without professional guidance.

What is asthma

Asthma is a chronic inflammatory condition of the airways characterised by variable and recurring episodes of wheeze, breathlessness, chest tightness, and cough.

The underlying pathology involves chronic eosinophilic airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction.

Triggers include allergens (house dust mites, pollen, pet dander), respiratory infections, cold air, exercise, air pollution, occupational exposures, and emotional stress.

Without effective anti-inflammatory treatment, chronic airway inflammation leads to structural changes known as airway remodelling, including subepithelial fibrosis, smooth muscle hypertrophy, and goblet cell hyperplasia.

These changes reduce the reversibility of airflow obstruction over time, making early and sustained preventer therapy essential for preserving long-term lung function.

Asthma in the UK

According to Asthma + Lung UK, the UK has one of the highest prevalence rates of asthma in the world, with approximately 1 in 11 people affected.

Asthma accounts for over 60,000 hospital admissions and approximately 1,400 deaths per year in the UK.

Many of these outcomes are preventable with optimal adherence to preventer therapy and appropriate personalised asthma action plans.

NICE, the BTS/SIGN guideline, and the Global Initiative for Asthma (GINA) all emphasise regular ICS use as the foundation of asthma management from Step 2 onwards.

How Clenil Modulite works: mechanism of action

Beclometasone dipropionate is a prodrug that is hydrolysed by pulmonary esterases to its active metabolite, beclometasone-17-monopropionate (B-17-MP).

B-17-MP binds to intracellular glucocorticoid receptors in airway epithelial cells, inflammatory cells, and smooth muscle cells.

The activated receptor complex translocates to the nucleus, where it modulates the transcription of genes involved in the inflammatory response.

The anti-inflammatory effects of inhaled beclometasone include suppression of pro-inflammatory cytokines (interleukins IL-4, IL-5, and IL-13), reduced recruitment and activation of eosinophils and mast cells, decreased mucus gland hypertrophy, restoration of epithelial integrity, and reduced bronchial hyperresponsiveness.

These effects accumulate over days to weeks of regular use, which is why Clenil Modulite must be taken consistently every day to be effective.

Clenil Modulite delivers a standard particle size aerosol (mass median aerodynamic diameter approximately 3 to 4 micrometres) that deposits primarily in the medium and large airways.

This is distinct from extra-fine particle formulations such as Qvar (beclometasone in a solution formulation with a particle size of approximately 1 micrometre), which achieve greater small airway penetration.

The two formulations are not interchangeable at the same microgram dose, and prescribers must specify the brand when prescribing inhaled beclometasone.

Clinical evidence and national guidelines

Inhaled beclometasone has been used in clinical practice since the 1970s and is one of the most extensively studied ICS molecules in respiratory medicine.

The BTS/SIGN British Guideline on the Management of Asthma and NICE Guideline NG80 (Asthma: diagnosis, monitoring and chronic asthma management) both recommend low-dose ICS as the first-line preventer therapy for adults and children with asthma who are symptomatic despite as-needed reliever use alone.

Clinical trials have consistently demonstrated that regular low-dose ICS therapy reduces asthma symptoms, improves peak expiratory flow rate (PEFR) and FEV1, decreases the frequency and severity of exacerbations, and reduces the risk of asthma-related hospitalisation and death.

The START study (Steroid Treatment As Regular Therapy) showed that early introduction of low-dose ICS in patients with recent-onset mild persistent asthma reduced the risk of severe exacerbations by 44% and improved lung function over 3 years compared with placebo.

NICE NG80 recommends a stepwise approach to asthma management. Clenil Modulite at a low dose (200 to 400 micrograms per day for adults) corresponds to Step 2.

If asthma remains uncontrolled at this step, the guideline recommends adding a long-acting beta-2 agonist (LABA) before increasing the ICS dose, rather than simply escalating the ICS dose alone.

At higher steps, combination inhalers containing both ICS and LABA may be preferred for convenience and adherence.

Dosage and administration

Clenil Modulite is available in four strengths: 50, 100, 200, and 250 micrograms per actuation. The dose is individualised based on asthma severity and treatment response, following the stepwise approach outlined in national guidelines.

Adults and adolescents (12 years and over)

The usual starting dose for mild to moderate asthma is 200 micrograms twice daily (total 400 micrograms per day).

In more severe asthma or when stepping down from higher treatment, the dose may be increased to a maximum of 1000 micrograms per day in divided doses.

Once asthma is well controlled (defined as minimal daytime symptoms, no night-time waking, no activity limitation, normal lung function, and infrequent reliever use), the dose should be stepped down gradually to the lowest effective maintenance dose.

Children (5 to 11 years)

The usual dose is 100 micrograms twice daily (total 200 micrograms per day). The maximum recommended dose in children is 400 micrograms per day.

Lower doses are preferred in paediatric patients to minimise the risk of systemic effects, and growth should be monitored regularly in children on prolonged ICS therapy.

Correct inhaler technique

Effective drug delivery depends on correct inhaler technique.

Studies have shown that up to 90% of patients make at least one error when using a pMDI, which can significantly reduce the amount of drug reaching the lungs.

Follow these steps for each dose.

• Remove the mouthpiece cap and shake the inhaler well for 5 seconds.
• If the inhaler is new or has not been used for 7 days or more, release one test spray into the air away from your face.
• Breathe out gently and fully, away from the inhaler.
• Place the mouthpiece between your lips and form a tight seal. Do not bite the mouthpiece.
• As you begin to breathe in slowly and deeply through your mouth, press the canister down once to release one dose.
• Continue to breathe in steadily for 3 to 5 seconds.
• Remove the inhaler from your mouth, hold your breath for about 10 seconds (or as long as is comfortable), then breathe out gently through your nose.
• If a second puff is required, wait approximately 30 seconds before repeating the process.
• Replace the mouthpiece cap after use.
• Rinse your mouth with water and spit. Do not swallow the rinse water.

Using a spacer device

A spacer is a plastic chamber that attaches to the inhaler mouthpiece.

It holds the aerosol cloud so that you can breathe it in more slowly, which increases lung deposition and reduces the amount of drug deposited in the mouth and throat.

Spacers are particularly recommended for children, elderly patients, anyone who finds it difficult to coordinate pressing the canister and breathing in, and patients who develop oral thrush or hoarseness despite good mouth rinsing technique.

The Aerochamber Plus and Volumatic are commonly used spacers compatible with Clenil Modulite.

Side effects of Clenil Modulite

Common side effects

The most frequently reported local side effects of inhaled beclometasone are oropharyngeal candidiasis (oral thrush) and dysphonia (hoarseness or voice changes).

Oral thrush occurs because the corticosteroid deposited in the oropharynx suppresses local immune defences, allowing Candida albicans to overgrow.

It presents as white patches on the tongue, inner cheeks, palate, or throat and may cause discomfort when eating or swallowing.

Treatment is with an antifungal mouthwash or lozenges (such as nystatin or miconazole oral gel). Using a spacer and rinsing the mouth after inhalation are effective preventive measures.

Uncommon side effects

Throat irritation, cough on inhalation, and an unpleasant taste may occur.

Paradoxical bronchospasm, a sudden tightening of the airways immediately after inhaling the medication, is rare but clinically important.

If this occurs, use your reliever inhaler immediately, stop using Clenil Modulite, and contact your prescriber. An alternative ICS or delivery device should be considered.

Systemic side effects

At recommended low to moderate doses, systemic absorption of inhaled beclometasone is minimal and clinically significant systemic effects are uncommon.

However, at high doses (above 800 micrograms per day in adults) or with prolonged treatment, the following systemic effects may occur: adrenal suppression, reduced bone mineral density (increasing the risk of osteoporotic fractures), posterior subcapsular cataracts, open-angle glaucoma, growth retardation in children, and easy skin bruising.

The risk of these effects increases with dose and duration of treatment, highlighting the importance of using the lowest effective dose.

Patients on high-dose ICS for prolonged periods should carry a steroid treatment card.

When to seek medical advice

Contact your GP, asthma nurse, or NHS 111 if you notice increasing use of your reliever inhaler, worsening symptoms despite regular preventer use, or new symptoms such as persistent hoarseness, mouth ulcers, or visual disturbance.

Seek emergency care (call 999 or attend A&E) if you have a severe asthma attack that does not respond to your reliever inhaler, you cannot speak in full sentences due to breathlessness, your lips or fingernails turn blue, or you feel drowsy or confused.

Warnings and precautions

Not a reliever

Clenil Modulite does not provide rapid relief of bronchospasm.

It is essential that all patients prescribed Clenil Modulite also have access to a short-acting beta-2 agonist (SABA) reliever inhaler for use during acute asthma episodes.

If you find yourself needing your reliever inhaler more than twice a week, your asthma may not be adequately controlled and you should seek a medication review.

Adrenal insufficiency risk

Prolonged use of high-dose inhaled corticosteroids can suppress the hypothalamic-pituitary-adrenal (HPA) axis.

Patients who are transferred from systemic corticosteroids to inhaled therapy may retain a degree of adrenal suppression for months.

During periods of physiological stress such as surgery, trauma, or severe infection, additional systemic steroid cover may be necessary.

Patients on high-dose ICS should carry a steroid treatment card and be aware of the symptoms of adrenal crisis, including severe fatigue, dizziness, nausea, vomiting, and collapse.

Infections

Inhaled corticosteroids may increase the susceptibility to or severity of certain infections.

Patients who have not had chickenpox or measles should avoid close contact with infected individuals and seek urgent medical advice if exposed.

Active pulmonary tuberculosis requires appropriate anti-tuberculous therapy before starting ICS treatment. Patients with untreated fungal, bacterial, or viral respiratory infections should have these treated before commencing Clenil Modulite.

Pregnancy and breastfeeding

Inhaled beclometasone has been widely used during pregnancy for many years and is generally considered safe for both mother and baby at recommended doses.

BTS/SIGN and NICE guidelines advise that preventer inhalers should be continued throughout pregnancy, as the risks of uncontrolled asthma (including pre-eclampsia, low birth weight, and preterm delivery) outweigh any theoretical risk from ICS treatment.

Beclometasone is present in breast milk in small quantities, but at therapeutic inhaled doses the amount transferred to the infant is negligible.

Breastfeeding mothers should continue their preventer inhaler as normal.

How to get a Clenil Modulite prescription in the UK

Clenil Modulite is classified as a prescription-only medicine (POM) in the UK and cannot be purchased over the counter.

The most common route is via your GP or asthma nurse during a routine asthma review.

If you are newly diagnosed with asthma, your clinician will assess your symptoms, perform spirometry and peak flow monitoring, and determine the appropriate step of treatment.

If you are already taking a preventer inhaler and require a repeat prescription, this can be arranged through your GP surgery, an authorised online prescriber registered with the GPhC, or through the NHS repeat prescriptions service.

All UK prescriptions for Clenil Modulite are dispensed by registered pharmacies.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Living with asthma: practical management

Using your preventer inhaler consistently is the single most important step in managing asthma effectively. In addition, the following strategies can help maintain good asthma control.

Identify and avoid your personal triggers where possible.

Keep a written personalised asthma action plan agreed with your GP or asthma nurse, detailing what to do when symptoms worsen.

Monitor your peak flow at home if advised by your clinician. Attend annual asthma reviews to ensure your treatment remains appropriate and your inhaler technique is correct.

Stopping smoking is the most effective lifestyle modification for people with asthma who smoke.

Smoking accelerates the decline in lung function, reduces the effectiveness of inhaled corticosteroids, and increases the frequency and severity of exacerbations.

The NHS offers free stop smoking services across the UK.

When to seek urgent medical advice

Asthma can be unpredictable.

Seek urgent medical help by calling 999 or attending A&E if you are having a severe asthma attack that does not improve with your reliever inhaler, you are too breathless to speak, eat, or sleep, your breathing is very fast, your reliever inhaler is not lasting 4 hours, or you feel frightened.

In less severe situations, contact your GP or NHS 111 if your symptoms are worsening over days, your reliever inhaler is needed more than three times a week, or you are waking at night with cough or wheeze.

Report any suspected adverse reactions to Clenil Modulite via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Clenil Modulite 200 micrograms, Summary of Product Characteristics (EMC)
• Beclometasone dipropionate, British National Formulary (BNF)
• NICE NG80: Asthma: diagnosis, monitoring and chronic asthma management
• BTS/SIGN British Guideline on the Management of Asthma
• Asthma, NHS
• MHRA Yellow Card Scheme